First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis

Bruton tyrosine kinase inhibitors (BTKi) are important treatment options in Waldenström's macroglobulinemia (WM). Whether second‐generation BTKi are associated with improved outcomes and/or better safety profile remains unclear. We did a systematic review and meta‐analysis of clinical trials that reported data on the outcomes of patients with WM who received either first‐ or second‐generation BTKi in the period between January 2010 and August 2021. Studies with twenty or fewer patients were excluded. The primary outcomes were efficacy measured by response and survival data. Eleven studies met the eligibility criteria and were included in the final analysis (n = 730 patients). A total of 298 patients received 1st‐generation BTKi and 432 received a 2nd‐generation BTKi. Pooled overall response rate (ORR) and major response rate (MRR) for both generations were similar (94.2% and 78.5% in 1st vs. 88.9% and 75.1% in 2nd, respectively). MRR for both generations was higher in MYD88 Mut/CXCR4 WT patients compared to MYD88 Mut/CXCR4 Mut patients (odds ratio [OR]: 3.9, 95% CI: 2.2 to 5.5). Pooled 18‐mo progression‐free survival (PFS) was similar for both generations (88.5% vs. 87.3%). Grade 3/4 atrial fibrillation was higher in 1st‐generation BTKi (3.1% vs. 0.4%); however, grade‐3/‐4 infections and neutropenia were more frequent in 2nd‐generarion BTKi (20.9% vs. 13.2%, 17.7% vs. 12%, respectively). The efficacy of 1st‐ and 2nd‐generation BTKis is comparable. The 1st‐generation BTKi were associated with a higher risk of atrial fibrillation, whereas infections and neutropenia occurred more frequently in 2nd‐generation BTKi.

[1]  M. Dimopoulos,et al.  Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Treon,et al.  Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia , 2021, Leukemia.

[3]  M. Dimopoulos,et al.  Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial , 2021, Clinical Cancer Research.

[4]  Shu Cheng,et al.  A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia , 2021, Clinical Cancer Research.

[5]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[6]  M. Kersten,et al.  WhiMSICAL: A global Waldenström's Macroglobulinemia patient‐derived data registry capturing treatment and quality of life outcomes , 2021, American journal of hematology.

[7]  M. Gertz.  Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management , 2020, American journal of hematology.

[8]  M. Dimopoulos,et al.  Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. , 2020, Blood advances.

[9]  C. Buske,et al.  CXCR4 in Waldenström’s Macroglobulinema: chances and challenges , 2020, Leukemia.

[10]  H. Heslop,et al.  Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. , 2020 .

[11]  R. Advani,et al.  Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[13]  M. Dimopoulos,et al.  A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY. , 2020, Blood.

[14]  W. Novotny,et al.  Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up. , 2020, Blood.

[15]  S. Iida,et al.  A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia , 2020, Cancer science.

[16]  W. Novotny,et al.  Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib. , 2020 .

[17]  S. Treon,et al.  Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Sun Ku Lee,et al.  Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. , 2019, The Lancet. Haematology.

[19]  S. Treon,et al.  CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib , 2019, British journal of haematology.

[20]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[21]  M. Dimopoulos,et al.  Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE. , 2019, Journal of Clinical Oncology.

[22]  M. Palomba,et al.  First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. , 2018, Hematology/oncology clinics of North America.

[23]  R. Advani,et al.  Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial , 2017 .

[24]  A. Roberts,et al.  BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) , 2017 .

[25]  M. Dimopoulos,et al.  Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. , 2017, The Lancet. Oncology.

[26]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[27]  Zhiwei Wang,et al.  Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor , 2015 .

[28]  R. Advani,et al.  Ibrutinib in previously treated Waldenström's macroglobulinemia. , 2015, The New England journal of medicine.

[29]  S. Treon,et al.  CXCR4 WHIM‐like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P‐directed survival signalling in Waldenström macroglobulinaemia cells , 2015, British journal of haematology.

[30]  A. Roccaro,et al.  C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. , 2014, Blood.

[31]  S. Rodig,et al.  The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia , 2014, Leukemia.

[32]  S. Treon,et al.  Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. , 2014, Blood.

[33]  E. Kimby,et al.  Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop , 2013, British journal of haematology.

[34]  P. Gobbi,et al.  Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. , 2003, Seminars in oncology.

[35]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .